Hot Technology Event: Microbiome Products Beyond FMT – Challenges & Opportunities

Microbiome-based therapies have been a hot area of research for the last decade and promising early-stage therapies are in clinical development. While these are great opportunities in this space to address patients’ unmet medical needs, there are significant challenges associated with delivering microbiome derived therapies to patients.

During this session, speakers will reflect on the cross-functional opportunities and significant challenges they faced in early development of microbiome products in addition to discussing future milestones and anticipated obstacles along the way. Speakers will elucidate some of their significant learnings so far and share some of the unresolved hurdles in translating these therapies from research to clinical development. Attendees will receive a real-world perspective on the development of microbiome products from peers who have been in their shoes.

Panelists:
Stephanie Culler, PhD, Co-Founder and CEO, Persephone Biome
Will DeLoache, PhD, Co-Founder and CEO, Novome Biotechnologies
Jeanette Mucha, CEO, CSO, and Co-Founder, SciBac

Moderators:
Claudia Fehling, MPH, Senior Consultant, Halloran Consulting Group
Anmol Grover, PhD, Lead Consultant, Halloran Consulting Group

Halloran Consulting Group makes life science companies better at what they do. Working with biopharma, medical device, and digital health companies, we understand that every organization has different needs. Halloran focuses on clinical, regulatory, strategic planning, and due diligence with younger clients, while offering direction and expertise to transform mature life science companies into more efficient organizations. Our seasoned experts provide the guidance crucial to long-term success.


Supporter: